




ACAN







ACE2




AGT




AGTR1




AGTR2




COL1




COL2





CTSD




IL-1b









IL8







IL-10




MAS1




MMP1



MMP3





Supplementary Figure S4. Gene expression analysis in human NP cells for Candesartan (1μM, 10μM, 100μM), the MAS-receptor agonist AVE 0991 (1μM, 10μM, 100μM), and the AGTR2-receptor agonist CGP-42112A (0.1μM, 1μM, 10μM) with 24 h of exposure in in-inflammatory settings (TNF-α addition). DMSO (0.1μL/ml, 1μL/ml, 10μL/ml; shown in μL volume on the x-axis) was used as the solvent control. Fold change values normalized to the baseline (day 0) are shown. n=4 biological replicates and n=3 technical replicates per donor were assessed. Mean and standard error of the mean (SEM) are shown. #: compared to Control; %: compared to TNF-α; &: compared to TNF-α+CGP42122A 0.1 μM; §: compared to TNF-α+CGP42122A 1 μM; †: compared to TNF-α+CGP42122A 10 μM; ?: compared to TNF-α+Candesartan 1 μM; +: compared to TNF-α+Candesartan 10 μM; ^: compared to TNF-α+Candesartan 100 μM; \$: compared to TNF-α+AVE0991 10 μM; !: compared to TNF-α+AVE0991 100 μM. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.